CMS Approves Medicare Add-On Payment for Aidoc CT Triage AI

The U.S. Centers for Medicare and Medicaid Services has approved a New Technology Add-on Payment for Aidoc's Clinical AI Reasoning Engine, marking a formal reimbursement pathway for AI-assisted CT triage under the federal Medicare program. The decision creates a direct billing mechanism for hospitals using the platform, a development that analysts and hospital administrators have watched closely as healthcare systems seek financial structures to sustain AI deployments.

What Happened

CMS granted the New Technology Add-on Payment, known as an NTAP, to Aidoc's Clinical AI Reasoning Engine. The NTAP designation is a Medicare mechanism designed to provide supplemental reimbursement for technologies that meet criteria for substantial clinical improvement and that are not yet fully reflected in standard diagnosis-related group payments. The approval applies to CT triage applications supported by the Aidoc platform, allowing hospitals to receive additional Medicare reimbursement on top of standard inpatient payments when the technology is used in qualifying cases.

Background

Aidoc is a medical AI company that provides clinical decision support tools deployed across hospital radiology and emergency care workflows. Its Clinical AI Reasoning Engine processes imaging data to flag time-sensitive conditions, including pulmonary embolism, intracranial hemorrhage, and large vessel occlusion, for faster radiologist and clinician review. The company has marketed its platform as infrastructure for what it calls an AI-enabled care pathway, integrating detection across multiple imaging studies and clinical data points rather than operating as a single-condition detection tool.

The NTAP program has historically been used by CMS to bridge the reimbursement gap for novel medical technologies during the period before utilization data is sufficient to update standard payment rates. To qualify, a technology must demonstrate that it represents a substantial clinical improvement over existing treatments or services and that its costs are not adequately covered under existing payment rates. Approval through this pathway does not constitute an FDA clearance determination, though Aidoc's underlying algorithms have received separate FDA clearances for individual clinical indications.

Healthcare AI reimbursement has been a persistent structural challenge for hospital adoption. Institutions have faced difficulty justifying recurring software expenditures when no direct Medicare billing code existed to offset costs. The absence of reimbursement pathways has been cited in industry discussions as one reason AI procurement has not translated into sustained, broad deployment despite years of investment in the sector.

What It Means in Practice

With the NTAP in place, hospitals that use Aidoc's Clinical AI Reasoning Engine during inpatient CT triage cases covered by Medicare can apply for the supplemental payment on qualifying discharges. The payment increment under NTAP is calculated as a percentage of the estimated cost that exceeds the standard DRG payment, with CMS policy setting that percentage at up to 65 percent of the excess cost for approved technologies.

The practical effect is that the reimbursement decision lowers the net cost burden on hospital systems using the platform for Medicare-covered patients, which represent a substantial share of inpatient volumes at most U.S. hospitals. Institutions already contracted with Aidoc may be able to apply the NTAP to existing deployments for eligible cases during the applicable fiscal year payment window.

The approval also establishes a precedent within the NTAP framework for AI-based clinical reasoning tools, separate from earlier NTAP decisions that addressed more narrowly defined software or device categories. Other AI radiology and triage platform companies may seek similar designations in future CMS rulemaking cycles.

CMS NTAP designations are reviewed annually as part of the agency's Inpatient Prospective Payment System rulemaking process, and the Aidoc approval will be subject to the standard reassessment timeline under that cycle.